Anti-Collagen II antibody (ab34712)

Overview

• Product nameAnti-Collagen II antibodySee all Collagen II primary antibodies ...
• Description
  Rabbit polyclonal to Collagen II
• SpecificityThis antibody reacts with Type II collagens and shows negligible (less than 1%) cross reactivity with Type I, III, IV, V or VI collagens. Nonspecific cross reaction with other human serum proteins or non collagen extracellular matrix proteins is negligible.
• Tested applicationsWB, ELISA, IP, IHC-P, ICC/IF more details
• Species reactivity
  Reacts with: Mouse, Chicken, Cow, Dog, Human
  Predicted to work with: all Mammals
• Immunogen

  Collagen Type II from human knee cartilage and bovine nasal cartilage.

Properties

• FormLiquid
• Storage instructionsStore at +4°C short term (1-2 weeks). Aliquot and store at -20°C or -80°C (add glycerol to a final volume of 50% for extra stability). Avoid repeated freeze / thaw cycles.
• Storage bufferPreservative: 0.01% Sodium Azide
  Constituents: 0.125M Sodium borate, 0.075M Sodium chloride, 0.005M EDTA. pH 8.0
• Concentration information loading...
• PurityImmunogen affinity purified
• Purification notesThis antibody was prepared by immunoaffinity chromatography using immobilized antigens followed by extensive cross adsorption against other collagens, human serum proteins and non collagen extracellular matrix proteins to remove any unwanted specificities.
• Clonality Polyclonal
• IsotypeIgG
• Research Areas
  • Stem Cells
  • Mesenchymal Stem Cells
  • Chondrogenesis

  • Signal Transduction
  • Cytoskeleton / ECM
  • Extracellular Matrix
  • ECM Proteins
  • Collagen

  • Signal Transduction
  • Cytoskeleton / ECM
  • Extracellular Matrix
  • Structures
  • Bone

Applications

Target

• FunctionType II collagen is specific for cartilaginous tissues. It is essential for the normal embryonic development of the skeleton, for linear growth and for the ability of cartilage to resist compressive forces.
• Tissue specificityIsoform 2 is highly expressed in juvenile chondrocyte and low in fetal chondrocyte.
• Involvement in diseaseDefects in COL2A1 are the cause of spondyloepiphyseal dysplasia congenital type (SEDC) [MIM:183900]. This disorder is characterized by disproportionate short stature and pleiotropic involvement of the skeletal and ocular systems.
  Defects in COL2A1 are the cause of spondyloepimetaphyseal dysplasia Strudwick type (SEMD-STR) [MIM:184250]. A bone disease characterized by disproportionate short stature from birth, with a very short trunk and shortened limbs, and skeletal abnormalities including lordosis, scoliosis, flattened vertebrae, pectus carinatum, coxa vara, clubfoot, and abnormal epiphyses or metaphyses. A distinctive radiographic feature is irregular sclerotic changes, described as dappled in the metaphyses of the long bones.
  Defects in COL2A1 are the cause of achondrogenesis type 2 (ACG2) [MIM:200610]; also known as achondrogenesis-hypochondrogenesis type II. ACG2 is a disease characterized by the absence of ossification in the vertebral column, sacrum and pubic bones.
  Defects in COL2A1 are the cause of Legg-Calve-Perthes disease (LCPD) [MIM:150600]; also known as Legg-Perthes disease or Perthes disease. LCPD is characterized by loss of circulation to the femoral head, resulting in avascular necrosis in a growing child. Clinical pictures of the disease vary, depending on the phase of disease progression through ischemia, revascularization, fracture and collapse, and repair and remodeling of the bone.
  Defects in COL2A1 are the cause of Kniest dysplasia (KD) [MIM:156550]; also known as Kniest syndrome or metatropic dwarfism type II. KD is a moderately severe chondrodysplasia phenotype that results from mutations in the COL2A1 gene. Characteristics of the disorder include a short trunk and extremities, mid-face hypoplasia, cleft palate, myopia, retinal detachment, and hearing loss.
  Defects in COL2A1 are a cause of primary avascular necrosis of femoral head (ANFH) [MIM:608805]; also known as ischemic necrosis of the femoral head or osteonecrosis of the femoral head. ANFH causes disability that often requires surgical intervention. Most cases are sporadic, but families in which there is an autosomal dominant inheritance of the disease have been identified. It has been estimated that 300,000 to 600,000 people in the United States have ANFH. Approximately 15,000 new cases of this common and disabling disorder are reported annually. The age at the onset is earlier than that for osteoarthritis. The diagnosis is typically made when patients are between the ages of 30 and 60 years. The clinical manifestations, such as pain on exertion, a limping gait, and a discrepancy in leg length, cause considerable disability. Moreover, nearly 10 percent of the 500,000 total-hip arthroplasties performed each year in the United States involve patients with ANFH. As a result, this disease creates a substantial socioeconomic cost as well as a burden for patients and their families.
  Defects in COL2A1 are the cause of osteoarthritis with mild chondrodysplasia (OACD) [MIM:604864]. Osteoarthritis is a common disease that produces joint pain and stiffness together with radiologic evidence of progressive degeneration of joint cartilage. Some forms of osteoarthritis are secondary to events such as trauma, infections, metabolic disorders, or congenital or heritable conditions that deform the epiphyses or related structures. In most patients, however, there is no readily identifiable cause of osteoarthritis. Inheritance in a Mendelian dominant manner has been demonstrated in some families with primary generalized osteoarthritis. Reports demonstrate coinheritance of primary generalized osteoarthritis with specific alleles of the gene COL2A1, the precursor of the major protein of cartilage.
  Defects in COL2A1 are the cause of platyspondylic lethal skeletal dysplasia Torrance type (PLSD-T) [MIM:151210]. Platyspondylic lethal skeletal dysplasias (PLSDs) are a heterogeneous group of chondrodysplasias characterized by severe platyspondyly and limb shortening. PLSD-T is characterized by varying platyspondyly, short ribs with anterior cupping, hypoplasia of the lower ilia with broad ischial and pubic bones, and shortening of the tubular bones with splayed and cupped metaphyses. Histology of the growth plate typically shows focal hypercellularity with slightly enlarged chondrocytes in the resting cartilage and relatively well-preserved columnar formation and ossification at the chondro-osseous junction. PLSD-T is generally a perinatally lethal disease, but a few long-term survivors have been reported.
  Defects in COL2A1 are the cause of multiple epiphyseal dysplasia with myopia and conductive deafness (EDMMD) [MIM:132450]. Multiple epiphyseal dysplasia is a generalized skeletal dysplasia associated with significant morbidity. Joint pain, joint deformity, waddling gait, and short stature are the main clinical signs and symptoms. EDMMD is an autosomal dominant disorder characterized by epiphyseal dysplasia associated with progressive myopia, retinal thinning, crenated cataracts, conductive deafness.
  Defects in COL2A1 are the cause of spondyloperipheral dysplasia (SPD) [MIM:271700]. SPD patients manifest short stature, midface hypoplasia, sensorineural hearing loss, spondyloepiphyseal dysplasia, platyspondyly and brachydactyly.
  Defects in COL2A1 are the cause of Stickler syndrome type 1 (STL1) [MIM:108300]; also known as vitreous type 1, or membranous vitreous type. STL1 is an autosomal dominant form of Stickler syndrome, an inherited disorder that associates ocular signs with more or less complete forms of Pierre Robin sequence, bone disorders and sensorineural deafness. Ocular disorders may include juvenile cataract, myopia, strabismus, vitreoretinal or chorioretinal degeneration, retinal detachment, and chronic uveitis. Robin sequence includes an opening in the roof of the mouth (a cleft palate), a large tongue (macroglossia), and a small lower jaw (micrognathia). Bones are affected by slight platyspondylisis and large, often defective epiphyses. Juvenile joint laxity is followed by early signs of arthrosis. The degree of hearing loss varies among affected individuals and may become more severe over time. Syndrome expressivity is variable.
  Defects in COL2A1 are the cause of Stickler syndrome type 1 non-syndromic ocular (STL1O) [MIM:609508]. STL1O is an autosomal dominant form of Stickler syndrome characterized by the ocular signs typically seen in STL1 such as cataract, myopia, retinal detachment. STL1 systemic features of premature osteoarthritis, cleft palate, hearing impairment, and craniofacial abnormalities are either absent or very mild in STL1O patients.
  Defects in COL2A1 are a cause of rhegmatogenous retinal detachment autosomal dominant (DRRD) [MIM:609508]. Rhegmatogenous retinal detachment most frequently results from a break or tear in the retina that allows fluid from the vitreous humor to enter the potential space beneath the retina. It is often associated with pathologic myopia and in most cases leads to visual impairment or blindness if untreated.
• Sequence similaritiesBelongs to the fibrillar collagen family.
  Contains 1 fibrillar collagen NC1 domain.
  Contains 1 VWFC domain.
• Post-translational
  modificationsProline residues at the third position of the tripeptide repeating unit (G-X-Y) are hydroxylated in some or all of the chains. Proline residues at the second position of the tripeptide repeating unit (G-X-Y) are hydroxylated in some of the chains.
  The N-telopeptide is covalently linked to the helical COL2 region of alpha 1(IX), alpha 2(IX) and alpha 3(IX) chain. The C-telopeptide is covalently linked to an another site in the helical region of alpha 3(IX) COL2.
• Cellular localizationSecreted > extracellular space > extracellular matrix.

Target information above from: UniProt accession P02458 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010) .

Information by UniProt
• Database links
  • Entrez Gene: 395069 Chicken
  • Entrez Gene: 407142 Cow
  • Entrez Gene: 1280 Human
  • Entrez Gene: 12824 Mouse
  • Omim: 120140 Human
  • SwissProt: P02459 Cow
  • SwissProt: P02458 Human
  • SwissProt: P28481 Mouse

  • Unigene: 408182 Human
  • Unigene: 2423 Mouse

  see all

• Alternative names
  Alpha 1 type II collagen antibodyAlpha-1 type II collagen antibodyAOM antibody

  Cartilage collagen antibodyChondrocalcin antibodyCO2A1_HUMAN antibodyCOL11A3 antibodyCOL2A1 antibodyCOL2A1 protein antibodyCollagen alpha 1(II) chain precursor antibodyCollagen II alpha 1 polypeptide antibodyCollagen type II alpha 1 (primary osteoarthritis spondyloepiphyseal dysplasia congenital) antibodyMGC131516 antibodySEDC antibody

  see all

Anti-Collagen II antibody images

• 

  Immunocytochemistry/ Immunofluorescence - Collagen II antibody (ab34712)This image is courtesy of an anonymous Abreview
  ab34712 staining Collagen II in Chicken embryonic sternal chondrocyte P17 cells by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with paraformaldehyde, permeabilzed with PBS + Tween 20 and blocked with 6% serum for 1 hour at 4°C. Samples were incubated with primary antibody (1/200) for 8 hours at 4°C. An Alexa Fluor^®594-conjugated goat anti-rabbit IgG polyclonal (1/1000) was used as the secondary antibody.

  See Abreview

• 

  Immunohistochemistry (Frozen sections) - Collagen II antibody (ab34712)Image courtesy of an anonymous Abreview.
  ab34712 at a 1/100 dilution staining Collagen II in murine brain tissue by Immunohistochemistry (Frozen sections).
  
  Tissue was fixed in methanol and blocked using 10% serum. A biotinylated secondary was used at a 1/500 dilution.
• 

  Immunocytochemistry/ Immunofluorescence - Anti-Collagen II antibody (ab34712)Image from Berg V et al., Arthritis Res Ther. 2010;12(6):R228. Epub 2010 Dec 30. Fig 1.; doi:10.1186/ar3215; 30 December 2010, Arthritis Research & Therapy 2010, 12:R228
  Immunofluorescence analysis of Human articular chondrocytes, staining Collagen II with ab34712.
  
  Cells were fixed with paraformaldehyde and blocked for 1 hour with 1% BSA. Cells were incubated with primary antibody overnight at 4°C. An AlexaFluor®594-conjugated goat anti-rabbit polyclonal IgG was used as the secondary antibody.